The participation of polymyxin B in combined antibiotic action.

Abstract

Article1 July 1954THE PARTICIPATION OF POLYMYXIN B IN COMBINED ANTIBIOTIC ACTIONERNEST JAWETZ, M.D., Ph.D., VIRGINIA COLEMAN, B.A., JANET B. GUNNISON, M.A.ERNEST JAWETZ, M.D., Ph.D.Search for more papers by this author, VIRGINIA COLEMAN, B.A.Search for more papers by this author, JANET B. GUNNISON, M.A.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-41-1-79 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe polymyxins are a group of stable basic polypeptides isolated fromBacillus polymyxa.1Depending upon their amino acid composition, they have been designated by letters A, B, C, D and E. Polymyxins A and D possess significant nephrotoxic action and are no longer employed in therapy. Polymyxins B and E produce annoying, though harmless, neurotoxic side effects but are not significantly nephrotoxic if administered intramuscularly in doses not exceeding 2.5 mg./kg./day to persons with good renal function.2, 3These drugs are rapidly bactericidal for gram-negative organisms and have been particularly useful in the management of infections due toPseudomonas aeruginosa.3,...Bibliography1. Stansly PG: The polymyxins, Am. J. Med. 1: 807, 1949. CrossrefGoogle Scholar2. HopperJawetzHinman JEF: Polymyxin B in chronic pyelonephritis: observations on the safety of the drug and on its influence on the renal infection, Am. J. M. Sc. 225: 302, 1953. CrossrefGoogle Scholar3. Jawetz E: Infections with Pseudomonas aeruginosa treated with polymyxin B, Arch. Int. Med. 89: 90, 1952. CrossrefGoogle Scholar4. Yow EM: Development of Proteus and Pseudomonas infections during antibiotic therapy, J. A. M. A. 149: 1184, 1952. CrossrefMedlineGoogle Scholar5. PulaskiBakerRosenbergConnell EJHJMLJF: Laboratory and clinical studies of polymyxin B and E, J. Clin. Investigation 28: 1028, 1949. CrossrefGoogle Scholar6. PriceRandallWelchChandler CWWAHVL: Studies of the combined action of antibiotics and sulfonamides, Am. J. Pub. Health 39: 340, 1949. CrossrefGoogle Scholar7. BlissWarthLong EAPTPH: Studies of combinations of antibiotics in vitro and in experimental infections in mice, Bull. Johns Hopkins Hosp. 90: 149, 1952. MedlineGoogle Scholar8. NeterKunzMorgan EEHED: Synergistic effects of polymyxin B and Terramycin on bacteria encountered in urinary tract infections, J. Urol. 67: 773, 1952. CrossrefMedlineGoogle Scholar9. JawetzGunnison EJB: Studies on antibiotic synergism and antagonism: a scheme of combined antibiotic action, Antibiotics and Chemotherapy 2: 243, 1952. Google Scholar10. Jawetz E: In preparation. Google Scholar11. GunnisonShevkyBruffColemanJawetz JBMCJAVRE: Studies on antibiotic synergism and antagonism: the effect in vitro of combinations of antibiotics on bacteria of varying resistance to single antibiotics, J. Bact. 66: 150, 1953. CrossrefMedlineGoogle Scholar12. JawetzGunnison EJB: Antibiotic synergism and antagonism: an assessment of the problem, Pharmacol. Rev. 5: 175, 1953. MedlineGoogle Scholar13. JawetzGunnison EJB: An experimental basis of combined antibiotic action (Report to the Council on Pharmacy and Chemistry of the A. M. A.), J. A. M. A. 150: 693, 1952. CrossrefMedlineGoogle Scholar14. RantzRandall LAE: Antibiotic synergism and Staphylococcus aureus , Antibiotics and Chemotherapy 2: 645, 1952. Google Scholar15. DowlingLepperJackson HFMHGG: When should antibiotics be used in combination? J. A. M. A. 151: 813, 1953. CrossrefMedlineGoogle Scholar16. Haviland JW: Advances in antibiotic therapy, Ann. Int. Med. 39: 307, 1953. LinkGoogle Scholar17. KleinSchorr MSE: The role of bacterial resistance in antibiotic synergism and antagonism, J. Bact. 65: 454, 1953. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: San Francisco, California*Received for publication November 6, 1953.Supported in part by grants from the National Institutes of Health (E-214), Burroughs, Wellcome and Co., and Chas. Pfizer and Co.From the Departments of Microbiology, Medicine and Pediatrics, University of California School of Medicine, San Francisco. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byA SYNERGIC PERSPECTIVEPolymyxins and CirculinPolymyxins and CirculinANTIBIOTICS ISOLATED FROM THE GENUS BACILLUS (BACILLACEAE)1 Polypeptide Antibiotics of Medicinal InterestOtogenic MeningitisPolymyxin, Colistin and BacitracinThe activity of some antibiotic combinations onSalmonellaPolymyxin, Neomycin and Bacitracin: Applied Pharmacology 1 July 1954Volume 41, Issue 1Page: 79-88KeywordsAdverse reactionsAmino acidsAntibioticsBacillusMicrobiologyPediatricsPolymyxinsPolypeptidesPseudomonasPseudomonas infections Issue Published: 1 July 1954 PDF downloadLoading ...